NCT07116473View on ClinicalTrials.gov

To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

November 30, 2037

Study Completion Date

December 31, 2037

Conditions
Amyloidosis in Transthyretin (TTR)Amyloidosis, FamilialAmyloid CardiomyopathyAmyloid Cardiomyopathy, Transthyretin-RelatedAmyloidogenic Transthyretin (ATTR) AmyloidosisHeart DiseaseCardiomyopathiesAmyloidosis, Hereditary, Transthyretin-RelatedPolyneuropathiesAmyloidosis
Interventions
DRUG

Acoramidis (AG10)

TTR stabilizer administered orally twice daily (BID)

All Listed Sponsors
lead

Eidos Therapeutics, a BridgeBio company

INDUSTRY